Leucogenum
- Generic Name
- Leucogenum
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于防治各种原因引起的白细胞减少症，再生障碍性贫血及血小板减少症。
- Associated Conditions
- -
- Associated Therapies
- -
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 132
- Registration Number
- NCT05780294
- Locations
- 🇨🇳
Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath